Synergistic Effects of PPAR Ligands and Retinoids in Cancer Treatment
Figure 3
A hypothetical schematic representation of
the synergistic anticancer effects of the combination of PPAR ligands plus
other agents. When PPARs are activated
by ligand binding, they are able to heterodimerize with RXR and activate the target
gene expression by binding to the PPRE element.
Therefore, the retinoids which bind to RXR may be the most preferable
partner for the PPAR agonists (A).
However, in some types of cancers, the MAPK pathway phosphorylates RXRα,
and the accumulated nonfunctional p-RXRα
interferes with the function of the remaining normal RXRα,
thereby promoting the growth of cancer cells. The activation of RTKs by their specific
ligands (growth factors) can play a critical role in the stimulation of the
MAPK pathway. Therefore, the agents
which target the activation of RTKs (B) and/or the MAPK pathway
(C)
restore the function of RXRα
as a master regulator of nuclear receptors in cancer cells and this will
support the synergistic growth inhibition by PPAR and
RXR ligands in cancer cells. The HDACs
enforce a tight chromatin structure and thereby repress the transcription of
target genes controlled by PPAR/RXR.
Therefore, the combination of a PPAR
agonist plus an HDAC inhibitor is more efficient to inhibit the growth of
cancer cells (D). Finally, the
conventional chemotherapeutic agents also cause synergistic or enhancing effects to inhibit
cancer cell growth by the combination of PPAR ligands (E). L: ligand.